Activator Protein-1. Possible Mechanism for Acceleration of Atherosclerosis by Subclinical Endotoxemia. Circ Res 107: 56–65. 20. Davis RJ (2000) Signal Transduction by the JNK Group of MAP Kinases. Cell 103: 239–252. 21. Huang W, Ghisletti S, Perissi V, Rosenfeld MG, Glass CK (2009) Transcriptional Integration of TLR2 and TLR4 Signaling at the NCoR Derepression Checkpoint. Molecular Cell 35: 48–57. 22. Sweeney SE, Hammaker D, Boyle DL, Firestein GS (2005) Regulation of c-Jun Phosphorylation by the IkappaB Kinase-epsilon Complex in Fibroblast-Like Synoviocytes. The Journal of Immunology 174: 6424–6430. 23. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J (2002) Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 4: 556–564. 24. Tanos T, Marinissen MJ, Leskow FC, Hochbaum D, Martinetto H, et al. (2005) Phosphorylation of c-Fos by Members of the p38 MAPK Family. J Biol Chem 280: 18842–18852. 25. Schromm AB, Lien E, Henneke P, Chow JC, Yoshimura A, et al. (2001) Molecular Genetic Analysis of an Endotoxin Nonresponder Mutant Cell Line. J Exp Med 194: 79–88. Syk Regulates AP-1 Dependent Response to mmLDL 26. Miller YI (2005) Toll-like receptors and atherosclerosis: oxidized LDL as an endogenous Toll-like receptor ligand. Future Cardiology 1: 785–792. 27. Harkewicz R, Hartvigsen K, Almazan F, Dennis EA, Witztum JL, et al. (2008) Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized LDL. J Biol Chem 283: 10241–10251. 28. Faggioli L, Costanzo C, Donadelli M, Palmieri M (2004) Activation of the interleukin-6 promoter by a dominant negative mutant of c-Jun. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1692: 17–24. 29. Ulanova M, Asfaha S, Stenton G, Lint A, Gilbertson D, et al. (2007) Involvement of Syk protein tyrosine kinase in LPS-induced responses in macrophages. J Endotoxin Res 13: 117–125. 30. Lin YC, Huang DY, Chu CL, Lin WW (2010) Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors- mediated JNK signaling pathway. Mol Immunol 47: 1569–1578. 31. Hilgendorf I, Eisele S, Remer I, Schmitz J, Zeschky K, et al. (2011) The Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib Attenuates Inflammation and Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice. Arterio- scler Thromb Vasc Biol 31: 1991–1999. PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32378